Cannabidiol use in France in 2022: Results from a nationwide representative sample of adults

Author:

Barré Tangui1ORCID,Lahaie Emmanuel2,Di Beo Vincent1,Carrieri Patrizia1,Andler Raphaël2,Nguyen‐Thanh Viêt2,Beck François23

Affiliation:

1. Aix‐Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM Marseille France

2. Santé Publique France Saint‐Maurice France

3. Centre de Recherche en Épidémiologie et Santé des Populations, Inserm U1018, Université Paris‐Saclay, Université Paris‐Sud Université Versailles Saint‐Quentin Villejuif France

Abstract

AbstractIntroductionCannabidiol (CBD) is a non‐intoxicating cannabis compound found in diverse commercial products worldwide. However, its use may not be fully harmless. Accordingly, it is important to document the prevalence of CBD use and user characteristics in the general population.MethodsWe conducted a nationwide survey from a random sample of adults living in France using computer‐assisted telephone interviews between 2 March and 9 July 2022. We estimated the prevalence of CBD awareness and CBD use, and explored the different routes of administration. We also performed logistic regression models to identify factors associated with past‐year CBD use.ResultsBased on data from 3229 participants, we estimated that 71.0% (95% confidence interval) (69.0–73.0) of the French adult population had heard of CBD, and 10.1% (8.7–11.4) had used it in the previous year. Past‐year CBD use was associated with younger age, a higher educational level, not living in a middle‐sized urban unit, tobacco consumption and e‐cigarette use. The most common route of administration was smoking (56.1%).Discussion and ConclusionPast‐year CBD use prevalence in France appeared to be as high as that for cannabis. Proper prevention, regulation and control of CBD products is necessary to ensure that people have access to safe and high‐quality products. Reliable information on CBD should be sought and disseminated, especially regarding the harms associated with smoking the compound.

Publisher

Wiley

Reference51 articles.

1. Cannabis sativa: The Plant of the Thousand and One Molecules

2. Cannabidiol Claims and Misconceptions

3. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials

4. Grand View Research.Cannabidiol Market Size Share And Growth Report 2030 [Internet]. 2023 [cited 25 August 2023]. Available from:https://www.grandviewresearch.com/industry-analysis/cannabidiol-cbd-market

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3